Clinical Trial Update: Titratable Dosing in Moderate to Severe Asthmatics [Phase 3]

View source ↗

Summary

AstraZeneca-sponsored Phase 3 trial evaluating titratable dosing in moderate-to-severe asthma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Snippet

Sponsor: AstraZeneca | Conditions: Asthma | Phase 3 | Status: COMPLETED